logo
Plus   Neg
Share
Email

Stock Alert: Will RedHill Biopharma Touch A New High

Shares of RedHill Biopharma Ltd.(RDHL) more than doubled from its 52-week low of $3.26, hit last month.

All pharma companies who are either developing drugs for the new coronavirus or those who are testing their already approved drug for the treatmnet, are seeing their shares moving higher on hopes of achieving the desired results.

Most recently, this Tuesday, RDHL touched its 52-week high of $9.12 on the news of its pipeline drug, opaganib showing clinical improvement in patients with SARS-CoV-2 coronavirus infection.

Preliminary data were positive in all the six patients suffering from moderate-to-severe acute respiratory symptoms related to SARS-CoV-2 infection. They were treated with opaganib in a 14 day comppassionate-use program.

The company has submitted an investigational New Drug Application (NDA) to the FDA to evaluate the safety and efficacy of opaganib in a randomized, double-blind, placebo-controlled Phase IIA study in patients hospitalized with positive SARS-CoV-2 and pneumonia in the U.S.

Clinical studies are also being planned in Israel and Italy.

On April 28, RedHill said its H.pylori drug Talicia has been added to Prime Therapeutics NetResults national formulary.

Wednesday, RDHL was up $0.27 or 3.52% before closing at $7.93.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has unveiled Instagram Reels as its answer to the popular Chinese-owned video app TikTok. The social media giant said in a blog post that Instagram Reels is a new way to create short, entertaining videos on Facebook's photo-sharing app Instagram. Facebook reportedly shut down its TikTok clone Lasso in July, ahead of the launch of Instagram Reels. WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020.
Follow RTT